Aquestive Therapeutics (AQST) FCF Margin (2017 - 2026)

Aquestive Therapeutics has reported FCF Margin for 10 years, with the latest figure at 69.85% in Q2 2026.

• On a quarterly basis, FCF Margin rose 1033.0% year-over-year to 69.85% in Q2 2026; TTM through Jun 2026 was 84.95%, a 2839.0% increase from a year earlier, with the FY2025 full-year figure at 118.97%, down 5657.0% from the prior year.
• FCF Margin was 69.85% for Q2 2026 at Aquestive Therapeutics, up from 102.85% in the prior quarter.
• The five-year high for FCF Margin was 79.16% in Q1 2023, with the low at 269.9% in Q1 2025.
• Average FCF Margin over 5 years is 59.42%, with a median of 65.84% recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: FCF Margin soared 19804 bps in 2023, then tumbled 18350 bps in 2025.
• Over 5 years, FCF Margin stood at 78.54% in 2022, then plunged by 148 bps to 37.54% in 2023, then plunged by 46 bps to 54.81% in 2024, then fell by 20 bps to 65.72% in 2025, then fell by 6 bps to 69.85% in 2026.
• The last three FCF Margin figures came in at 69.85% (Q2 2026), 102.85% (Q1 2026), and 65.72% (Q4 2025), per Business Quant data.